Hims & Hers Health (NYSE:HIMS) CFO Oluyemi Okupe Sells 7,950 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) CFO Oluyemi Okupe sold 7,950 shares of the business’s stock in a transaction that occurred on Monday, May 18th. The stock was sold at an average price of $23.64, for a total transaction of $187,938.00. Following the sale, the chief financial officer owned 262,954 shares of the company’s stock, valued at approximately $6,216,232.56. This represents a 2.93% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Oluyemi Okupe also recently made the following trade(s):

• On Monday, April 20th, Oluyemi Okupe sold 19,645 shares of Hims & Hers Health stock. The stock was sold at an average price of $29.96, for a total transaction of $588,564.20.
• On Thursday, April 16th, Oluyemi Okupe sold 36,922 shares of Hims & Hers Health stock. The stock was sold at an average price of $25.90, for a total transaction of $956,279.80.
• On Friday, April 17th, Oluyemi Okupe sold 18,005 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.83, for a total transaction of $501,079.15.
• On Monday, April 6th, Oluyemi Okupe sold 3,975 shares of Hims & Hers Health stock. The stock was sold at an average price of $19.98, for a total transaction of $79,420.50.
• On Friday, March 20th, Oluyemi Okupe sold 9,217 shares of Hims & Hers Health stock. The stock was sold at an average price of $23.77, for a total transaction of $219,088.09.

Hims & Hers Health Price Performance

HIMS opened at $22.47 on Wednesday. The company has a quick ratio of 1.56, a current ratio of 1.69 and a debt-to-equity ratio of 2.18. Hims & Hers Health, Inc. has a 52-week low of $13.74 and a 52-week high of $70.43. The company has a 50 day moving average of $24.05 and a two-hundred day moving average of $28.43. The company has a market cap of $5.12 billion, a P/E ratio of -249.61, a P/E/G ratio of 39.32 and a beta of 2.43.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 11th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.04 by ($0.44). Hims & Hers Health had a positive return on equity of 6.10% and a negative net margin of 0.56%.The business had revenue of $608.10 million for the quarter, compared to analysts’ expectations of $616.84 million. During the same quarter in the prior year, the firm earned $0.20 earnings per share. Hims & Hers Health’s quarterly revenue was up 3.8% compared to the same quarter last year. On average, analysts expect that Hims & Hers Health, Inc. will post 0.04 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several research analysts have recently weighed in on HIMS shares. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a research note on Wednesday, February 25th. Canaccord Genuity Group set a $32.00 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Citigroup upped their target price on shares of Hims & Hers Health from $24.00 to $28.00 and gave the company a “neutral” rating in a research note on Tuesday, May 12th. Jefferies Financial Group set a $24.50 target price on shares of Hims & Hers Health in a research note on Tuesday, May 12th. Finally, Weiss Ratings downgraded shares of Hims & Hers Health from a “hold (c)” rating to a “sell (d)” rating in a research note on Tuesday, May 12th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $29.37.

More Hims & Hers Health News

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The larger financing gives Hims & Hers more capital to pursue international expansion, acquisition plans, and technology investment without using as much operating cash. Hims & Hers Health, Inc. Prices Upsized $350 Million Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment
• Neutral Sentiment: Bank of America lowered its price target on Hims & Hers to $28 from $30 and kept a neutral rating, signaling more cautious expectations even though the target still sits above the recent share price. Benzinga report on Bank of America price target cut
• Negative Sentiment: Investors are worried the convertible notes could dilute shareholders later, which has contributed to the stock sliding after the financing announcement. Why Hims & Hers Stock Is Falling Today
• Negative Sentiment: The company’s latest earnings call and recent Q1 results have also kept sentiment weak, with the market still focused on the prior quarter’s earnings miss and softer-than-expected revenue. Hims & Hers Health, Inc. Announces Proposed Convertible Senior Notes Offering to Support International Expansion and Accelerate AI-Driven Platform Investment

Institutional Trading of Hims & Hers Health

Several institutional investors have recently added to or reduced their stakes in the stock. Vanguard Group Inc. raised its holdings in Hims & Hers Health by 7.2% in the fourth quarter. Vanguard Group Inc. now owns 20,925,666 shares of the company’s stock valued at $679,456,000 after acquiring an additional 1,407,651 shares in the last quarter. Capital World Investors raised its holdings in Hims & Hers Health by 1.2% in the third quarter. Capital World Investors now owns 18,783,194 shares of the company’s stock valued at $1,065,399,000 after acquiring an additional 223,892 shares in the last quarter. Farallon Capital Management LLC raised its holdings in Hims & Hers Health by 30.8% in the third quarter. Farallon Capital Management LLC now owns 10,746,852 shares of the company’s stock valued at $609,561,000 after acquiring an additional 2,533,271 shares in the last quarter. State Street Corp raised its holdings in Hims & Hers Health by 1.8% in the fourth quarter. State Street Corp now owns 7,305,525 shares of the company’s stock valued at $237,210,000 after acquiring an additional 132,311 shares in the last quarter. Finally, Geode Capital Management LLC raised its holdings in Hims & Hers Health by 12.4% in the fourth quarter. Geode Capital Management LLC now owns 5,509,764 shares of the company’s stock valued at $183,485,000 after acquiring an additional 608,950 shares in the last quarter. 63.52% of the stock is owned by institutional investors and hedge funds.

About Hims & Hers Health

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.